Drugs /

temsirolimus

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
temsirolimus
Trade Name(s):
Torisel
NCI Definition [1]:
An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.

Clinical Trials

View Clinical Trials for temsirolimus

Temsirolimus has been investigated in 11 clinical trials, of which 10 are open and 1 is closed. Of the trials investigating temsirolimus, 2 are early phase 1 (2 open), 5 are phase 1 (4 open), 2 are phase 2 (2 open), and 2 are phase 3 (2 open).

AKT1 Mutation, MTOR Mutation, and PIK3CA Mutation are the most frequent biomarker inclusion criteria for temsirolimus clinical trials.

Malignant solid tumor, acute lymphoblastic leukemia, and alveolar rhabdomyosarcoma are the most common diseases being investigated in temsirolimus clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Temsirolimus
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Temsirolimus
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating temsirolimus and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cci-779, Torisel, temsirolimus [chemical/ingredient], rapamycin analog cci-779, cci 779, temsirolimus, cell cycle inhibitor 779, temsirolimus, 61010, rapamycin analog, 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin, temsirolimus (substance), 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin, 683864, 162635-04-3, temsirolimus (product), rapamycin analog cci-779, cci-779 rapamycin analog, cell cycle inhibitor 779, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin, wyeth brand of temsirolimus
Drug Categories [2]:
Allosteric mTORC1 inhibitors, Serine/threonine kinase inhibitors
Drug Target(s) [2]:
FKBP1A, MTOR
NCIT ID [1]:
C1844
SNOMED ID [1]:
C-781F8

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.